Peptide Monographs

CJC-1295 and Sermorelin side by side

CJC-1295 and Sermorelin are both indexed under GHRH analogues. Every cell below carries the record it came from, and an axis with no retrieved value reads Unknown rather than being filled by inference.

Summary

Both are analogues of the 1-29 fragment of growth hormone-releasing hormone acting at the GHRH receptor. Sermorelin is the unmodified 1-29 fragment; CJC-1295 carries modifications and a drug affinity complex that the cited 2006 Journal of Clinical Endocrinology and Metabolism paper reports as prolonging stimulation of growth hormone and IGF-I secretion.

[1, 2, 3, 4, 5]

Side by side

Curated comparison axes for CJC-1295 and Sermorelin
AxisCJC-1295Sermorelin
Reported mechanismA long-acting GHRH analogue that activates the GRF receptor; the retrieved literature attributes its extended duration of action to albumin bioconjugation.[8, 2]A growth hormone releasing factor analogue acting at the GHRH receptor on the anterior pituitary, upstream of growth hormone release.[13]
Molecular formulaC165H269N47O46[6]C149H246N44O42S[10]
Molecular weight3647.2 g/mol[6]3357.9 g/mol[10]
FDA application registerA query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[7]A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[11]

Where the two literatures diverge

Duration of action is the axis of divergence. The cited 2009 and 2006 records for CJC-1295 report sustained activation of the GH/IGF-1 axis with pulsatile secretion preserved, while the cited 1999 and 2006 sermorelin reviews cover its use in the diagnosis and management of growth hormone deficiency as a short-acting agent. Neither name returned an FDA application record on the retrieval date.

[1, 2, 3, 4, 5]

Where this page sits

Full pages: CJC-1295 and Sermorelin.

Shared class: GHRH analogues.

Other pairs in the same class

All side-by-side pages: index.

Sources

  1. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab (2006). pmid:16352683
  2. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res (2009). pmid:19386527
  3. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab (2006). pmid:17018654
  4. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs (1999). pmid:18031173
  5. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?. Clin Interv Aging (2006). pmid:18046908
  6. PubChem Compound Summary for CID 91971820, Cjc 1295. PubChem, National Library of Medicine (2026). pubchem:91971820
  7. Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:cjc-1295
  8. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology (2005). pmid:15817669
  9. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal (2010). pmid:21204297
  10. PubChem Compound Summary for CID 16132413, Sermorelin. PubChem, National Library of Medicine (2026). pubchem:16132413
  11. Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:sermorelin
  12. Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist. Endocrinology (1985). pmid:2859987
  13. Structural requirements for the activation of rat anterior pituitary adenylate cyclase by growth hormone-releasing factor (GRF): discovery of (N-Ac-Tyr1, D-Arg2)-GRF(1-29)-NH2 as a GRF antagonist on membranes. Endocrinology (1985). pmid:2994998
  14. A potentially effective drug for patients with recurrent glioma: sermorelin. Ann Transl Med (2021). pmid:33842627

On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.

Related resources